Long-term oncological outcomes following percutaneous microwave ablation of T1 renal cell carcinoma
British Journal of Radiology · 2025
DOI: 10.1093/bjr/tqaf214 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Radiology, 2025. Verfasst von Luke Glover und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Imaging, Royal Devon University Healthcare NHS Foundation Trust, Exeter EX2 5DW, United Kingdom. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms, Microwaves, Ablation Techniques. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objectives
Incidence of small renal masses (SRMs) including renal cell carcinoma (RCC) is increasing. Standard of care is to offer partial nephrectomy (PN), with tumour ablation (TA) considered an alternative in frail/co-morbid patients. This study aimed to determine whether microwave ablation (MWA) is a safe and effective treatment for selected cases of RCC.
Methods
All MWAs performed at a regional tertiary care centre between October 2016 and April 2024 were prospectively recorded on a database. Data collected included tumour and patient characteristics, complications, and recurrences.
Results
Two hundred and nine MWAs were recorded with median 37 months (interquartile range [IQR] 15.3-59.4 months) follow-up. About 94.7% of patients had ≥12 months of follow-up. The biopsy rate was 92%. Following MWA, 93% of patients had a hospital stay of 1 night. Two Clavien-Dindo grade ≥III complications occurred within 30 days (0.96%). Local and metastatic recurrence rates were 5.9% and 2.7%, respectively.
Conclusions
MWA was a safe, effective treatment for SRMs in this large cohort which included young, fit patients and underwent long-term follow-up. Recovery times were short, with low complication rates and favourable oncological outcomes in biopsy-proven T1 RCC <5 cm. Advances in knowledge The current study demonstrates a large, diverse MWA cohort (including T1b tumours) with high biopsy rate, minimal loss to follow-up, and long follow-up period facilitating assessment of long-term oncological outcomes in biopsy-proven RCC. The results support MWA as a safe, effective treatment for cT1a RCC that should be offered to patients as part of shared decision making.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Imaging, Royal Devon University Healthcare NHS Foundation Trust, Exeter EX2 5DW, United Kingdom.
- South West Imaging Training Academy, Plymouth PL6 5WR, United Kingdom.
- Department of Urology, Royal Devon University Healthcare NHS Foundation Trust, Exeter EX2 5DW, United Kingdom.
- University of Exeter Medical School, St Luke's Campus, Exeter, EX1 2LU, United Kingdom.
ORCID-Profile: Luke Glover
Zitieren
APA
Glover, L., John, J., Spiers, A., Guinness, R., Dutton, T., Gemmell, A., Virdi, R., Skinner, J., Anderson, M., Stainer-Smith, T., & Campain, N. (2025). Long-term oncological outcomes following percutaneous microwave ablation of T1 renal cell carcinoma. British Journal of Radiology. https://doi.org/10.1093/bjr/tqaf214
Vancouver
Glover L, John J, Spiers A, Guinness R, Dutton T, Gemmell A, et al. Long-term oncological outcomes following percutaneous microwave ablation of T1 renal cell carcinoma. British Journal of Radiology. 2025. doi:10.1093/bjr/tqaf214
BibTeX
@article{Glover2025,
author = {Glover, Luke and John, Joseph and Spiers, Alexander and Guinness, Richard and Dutton, Thomas and Gemmell, Andrew and Virdi, Rajinder and Skinner, Jonathan and Anderson, Moira and Stainer-Smith, Taona and Campain, Nicholas},
title = {Long-term oncological outcomes following percutaneous microwave ablation of T1 renal cell carcinoma},
journal = {British Journal of Radiology},
year = {2025},
doi = {10.1093/bjr/tqaf214}
}
EUVIMED